

University of Dundee

## Identification of Novel *Trypanosoma cruzi* Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay

Zmuda, Filip; Sastry, Lalitha; Shepherd, Sharon M.; Jones, Deuan; Scott, Alison; Craggs, Peter D.

*Published in:*  
Antimicrobial Agents and Chemotherapy

*DOI:*  
[10.1128/AAC.00309-19](https://doi.org/10.1128/AAC.00309-19)

*Publication date:*  
2019

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*  
Zmuda, F., Sastry, L., Shepherd, S. M., Jones, D., Scott, A., Craggs, P. D., ... De Rycker, M. (2019). Identification of Novel *Trypanosoma cruzi* Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay. *Antimicrobial Agents and Chemotherapy*, 63(9), 1-15. [e00309-19]. <https://doi.org/10.1128/AAC.00309-19>

### General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



# Identification of Novel *Trypanosoma cruzi* Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay

Filip Zmuda,<sup>a</sup> Lalitha Sastry,<sup>a</sup> Sharon M. Shepherd,<sup>b</sup> Deuan Jones,<sup>a</sup> Alison Scott,<sup>b</sup> Peter D. Craggs,<sup>c</sup> Alvaro Cortes,<sup>c</sup> David W. Gray,<sup>a</sup> Leah S. Torrie,<sup>a</sup>  Manu De Rycker<sup>a</sup>

<sup>a</sup>Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, United Kingdom

<sup>b</sup>Protein Production Team, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, United Kingdom

<sup>c</sup>Screening Compound Profiling and Mechanistic Biology, Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom

**ABSTRACT** Chagas' disease, caused by the protozoan parasite *Trypanosoma cruzi*, is a potentially life-threatening condition that has become a global issue. Current treatment is limited to two medicines that require prolonged dosing and are associated with multiple side effects, which often lead to treatment discontinuation and failure. One way to address these shortcomings is through target-based drug discovery on validated *T. cruzi* protein targets. One such target is the proteasome, which plays a crucial role in protein degradation and turnover through chymotrypsin-, trypsin-, and caspase-like catalytic activities. In order to initiate a proteasome drug discovery program, we isolated proteasomes from *T. cruzi* epimastigotes and characterized their activity using a commercially available glow-like luminescence-based assay. We developed a high-throughput biochemical assay for the chymotrypsin-like activity of the *T. cruzi* proteasome, which was found to be sensitive, specific, and robust but prone to luminescence technology interference. To mitigate this, we also developed a counterscreen assay that identifies potential interferers at the levels of both the luciferase enzyme reporter and the mechanism responsible for a glow-like response. Interestingly, we also found that the peptide substrate for chymotrypsin-like proteasome activity was not specific and was likely partially turned over by other catalytic sites of the protein. Finally, we utilized these biochemical tools to screen 18,098 compounds, exploring diverse drug-like chemical space, which allowed us to identify 39 hits that were active in the primary screening assay and inactive in the counter-screen assay.

**KEYWORDS** Chagas' disease, *Trypanosoma cruzi*, assay development, drug discovery, drug screening, pharmacology, proteasome

Chagas' disease is a parasitic disease caused by the kinetoplastid parasite *Trypanosoma cruzi*. The disease is a problem, not only in the regions of endemicity in Latin America, but also more globally because of migration (1, 2). Disease progression is characterized by an initial acute phase, with symptoms such as fever and local inflammation, followed by a long, symptomless indeterminate phase. In a subset of people, the disease develops into a symptomatic, chronic phase with cardiomyopathy and mega-organ disease as the main manifestations. Approximately 2% of infected people develop cardiac problems annually (3), with an associated death toll of around 10,000 per year (2). Treatment for Chagas' disease is currently limited to the two nitroheterocyclic drugs benznidazole and nifurtimox. Benznidazole is typically used as front-line treatment, as it is better tolerated than nifurtimox, notwithstanding a 10% treatment discontinuation rate due to its own side effects (4). New, better-tolerated medicines are

**Citation** Zmuda F, Sastry L, Shepherd SM, Jones D, Scott A, Craggs PD, Cortes A, Gray DW, Torrie LS, De Rycker M. 2019. Identification of novel *Trypanosoma cruzi* proteasome inhibitors using a luminescence-based high-throughput screening assay. *Antimicrob Agents Chemother* 63:e00309-19. <https://doi.org/10.1128/AAC.00309-19>.

**Copyright** © 2019 Zmuda et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to David W. Gray, [d.w.gray@dundee.ac.uk](mailto:d.w.gray@dundee.ac.uk), or Manu De Rycker, [m.derycker@dundee.ac.uk](mailto:m.derycker@dundee.ac.uk).

**Received** 20 February 2019

**Returned for modification** 1 April 2019

**Accepted** 5 July 2019

**Accepted manuscript posted online** 15 July 2019


**Published** 23 August 2019

urgently required, but their development has proven very difficult, as exemplified by the failure in clinical trials of the only two new candidate treatments, posaconazole and fos-avuconazole (5, 6). Many efforts are ongoing to identify new starting points for drug discovery, often through large-scale phenotypic screening (7–12). Target-based screening, where a particular protein is assayed in its purified state, is an alternative approach with the advantages of more straightforward understanding of chemical structure-activity relationships (SAR) due to the absence of cell membranes, a direct relationship between compound affinity and target inhibition or binding, and the opportunity to generate structural information to guide chemistry design. Lack of translation of target inhibition to parasite death is an important risk when investing in such a program, and selecting well-validated targets is essential. One powerful method to identify suitable protein targets is by determining the modes of action of compounds that show the desired phenotypic effects in terms of parasite killing. Recently, the proteasome was identified as a promising drug target for kinetoplastid diseases through mode-of-action determination of promising phenotypically active compounds (GNF6702 and GSK3494245/DDD01305143) (9, 13). The proteasome is a key component of the ubiquitin-proteasome protein degradation system and plays an important role in many cellular processes, including protein turnover and cell signaling (14). In eukaryotes, the proteasome comprises a central 20S cylindrical structure and two regulatory 19S complexes on either end of the 20S core. The 20S unit is made up of two outer ( $\alpha$ ) and two inner ( $\beta$ ) polypeptide rings, where three of the  $\beta$ -type subunits are involved in chymotrypsin-, trypsin-, and caspase-like catalytic activities (15, 16). The proteasome is a well-exploited target in drug discovery for a variety of indications, including cancer, inflammation, and infectious diseases (17). In terms of parasitic diseases, the *Plasmodium* proteasome is well characterized, and proof of concept that selective inhibition is possible has opened the route to development of new malaria drugs targeting the proteasome (18). GNF6702 is active against *Leishmania donovani*, *Trypanosoma brucei*, and *T. cruzi* both *in vitro* and *in vivo* while showing no toxicity against mammalian cells, and GSK3494245/DDD01305143 is a preclinical candidate for visceral leishmaniasis developed from a *T. cruzi* screening hit, demonstrating that the proteasome is a suitable drug target across the kinetoplastid parasites. These compounds exert their effects on the parasites through the selective inhibition of the chymotrypsin-like activity of the parasite proteasome, and not the caspase- or trypsin-like activity (9, 13).

Attrition in drug discovery programs is high, and even compounds that demonstrate proof-of-concept efficacy in animal models frequently fail at later stages in the drug development process, often for non-target-related reasons (19). Once a validated target has been identified, it is therefore sensible to generate multiple chemical classes of inhibitors. With this in mind, we have started a hit discovery program for the *T. cruzi* proteasome chymotrypsin-like activity. Here, we present the development of a luminescence-based high-throughput screening (HTS) assay using partially purified *T. cruzi* proteasomes, as well as a technology interference counterscreen assay, which we then used to screen two diverse sets of compounds (18,098 compounds in total) in an effort to identify potential new starting points for a drug discovery program against Chagas' disease.

## RESULTS AND DISCUSSION


***T. cruzi* proteasome characterization.** Proteasomes were harvested from cleared epimastigote lysates through ultracentrifugation, followed by partial purification using size exclusion chromatography. In order to confirm the presence of enzymatic activity, chymotrypsin-, trypsin-, and caspase-like activities of the proteasome were measured using luminogenic versions of established peptide substrates (16, 20) and a commercially available glow response luminescence-based assay system (20). All three types of catalytic activities were found to be present in the pooled, partially purified *T. cruzi* proteasome material. To further profile the isolated protein, the catalytic activities of the proteasome were measured over time in the presence of the irreversible protea-



**FIG 1** Chymotrypsin-like (a), trypsin-like (b), and caspase-like (c) activities of the *T. cruzi* proteasome in the presence (black circles) and absence (red circles) of 5  $\mu\text{M}$  epoxomicin. Data are shown for 6 technical replicates ( $n = 6$ ); the error bars represent standard deviations (SD).

some inhibitor epoxomicin (21, 22). The degree of inhibition of the chymotrypsin-like activity was the highest, followed by trypsin- and caspase-like activities (Fig. 1), which is consistent with previous literature reports (22). The characteristic plateau of the kinetic curves in the absence of inhibitor compound corresponded to steady-state conditions, where the rate of substrate consumption by the proteasome was equal to the rate of product consumption by the luciferase reporter enzyme (20). In the case of chymotrypsin-like activity, steady-state conditions were established within approximately 15 min and were maintained for the remainder of the 75-min kinetic experiment.


**High-throughput primary screening assay development.** Following the validation of the *T. cruzi* proteasome purification and isolation methodology, we diverted our efforts toward the optimization of the commercially available proteasome chymotrypsin-like activity luminescence-based assay for HTS. In the presence of a fixed amount of chymotrypsin-like substrate (i.e., succinyl-Leu-Leu-Val-Tyr-aminoluciferin) and under steady-state conditions, the luminescence response was shown to be linearly proportional ( $R^2 = 0.9998$ ) to the amount of *T. cruzi* proteasome up to a top concentration equivalent to a 1-in-2 dilution of the stock material (i.e., a concentration multiplication factor [CMF] of 0.5) (Fig. 2a). Steady-state conditions were established rapidly for all of the tested concentrations of the *T. cruzi* proteasome and were maintained throughout the course of the kinetic experiment, with the exception of the top protein concentration (i.e., undiluted stock), where a drop-off in the luminescence response was observed after approximately 30 min (Fig. 2b). This loss of steady state was likely a consequence of substrate depletion. By varying the concentration of suc-Leu-Leu-Val-Tyr-aminoluciferin in the presence of a fixed amount of *T. cruzi* proteasome, substrate inhibition was observed at a concentration of 600  $\mu\text{M}$  under pre-steady-state conditions (Fig. 3a). This is in line with the work of Stein et al., who also reported proteasome chymotrypsin-like activity inhibition at high concentrations of a fluorescence-tagged variant of the suc-Leu-Leu-Val-Tyr peptide substrate (i.e., suc-Leu-Leu-Val-Tyr-AMC) (23). Utilizing



**FIG 2** Chymotrypsin-like activity plotted as a function of either *T. cruzi* proteasome concentration after a 60-min biochemical reaction (a) or time at different proteasome stock solution dilutions (b). Data are shown for 5 technical replicates ( $n = 5$ ); the error bars represent SD. Linear regression,  $R^2 = 0.999$ .

the Z factor as a measure of assay quality, where values of  $\geq 0.5$  are generally accepted as sufficient for HTS (24), a 1-in-8 dilution (CMF = 0.125) of the stock *T. cruzi* proteasome preparation and a suc-Leu-Leu-Val-Tyr-aminoluciferin substrate concentration of 20  $\mu\text{M}$  (final assay concentrations) were found to be optimal, affording Z factor values of  $> 0.75$  at steady state. Under these assay conditions, the apparent steady-state  $K_m$  for the suc-Leu-Leu-Val-Tyr-aminoluciferin substrate was found to be 93.5  $\mu\text{M}$  (95% confidence interval [CI] = 78.8 to 108.4  $\mu\text{M}$ ) (Fig. 3b), which was only marginally higher than the approximate value of 60  $\mu\text{M}$  that was reported by O'Brien et al. using a similar assay platform in a cellular system (20). Finally, as our screening compound libraries are formulated in dimethyl sulfoxide (DMSO), the tolerance of the biochemical assay for this solvent was investigated. We found that the maximum tested concentration of DMSO (1% [vol/vol] final assay concentration) was well tolerated by the system and had a negligible effect on the luminescence response (see Fig. S2 in the supplemental material).

**High-throughput primary screening assay validation.** In order to validate the biochemical assay and identify a suitable control inhibitor compound for HTS, chymotrypsin-, trypsin-, and caspase-like activity concentration-response relationships for a panel of commercially available proteasome inhibitors were established (Fig. 4; see Table S1 in the supplemental material). Of the tested compounds, oprozomib exhibited specificity for the *T. cruzi* proteasome chymotrypsin-like active sites, which is in line with previous literature reports (9, 25). Interestingly, the compound failed to completely abolish catalytic activity in this biochemical assay. It was hypothesized that the suc-Leu-Leu-Val-Tyr-aminoluciferin substrate was not specific for the chymotrypsin-like active site of the *T. cruzi* proteasome, and residual turnover of the substrate by the trypsin- and/or caspase-like active sites resulted in incomplete apparent inhibition of chymotrypsin-like activity. To investigate this further, steady-state chymotrypsin-like activity concentration-response relationships were established for oprozomib using 20  $\mu\text{M}$  and 600  $\mu\text{M}$  suc-Leu-Leu-Val-Tyr-aminoluciferin substrate. It was envisaged that in the presence of a specific chymotrypsin-like activity inhibitor, an increase in nonspecific luminogenic




**FIG 3** *T. cruzi* proteasome chymotrypsin-like activity plotted as a function of time in the presence of various concentrations of suc-Leu-Leu-Val-Tyr-aminoluciferin substrate (a) or as a function of the suc-Leu-Leu-Val-Tyr-aminoluciferin substrate concentration after a 60-min biochemical reaction fitted to the Michaelis-Menten model (apparent  $K_m = 93.5 \mu\text{M}$  [95% CI = 78.8 to 108.4  $\mu\text{M}$ ]) (b). Data are shown for 3 technical replicates ( $n = 3$ ); the error bars represent SD.

substrate would result in an increased residual luminescence response and, subsequently, a reduced upper concentration-response curve plateau. The marked reduction in the upper concentration-response curve plateaus following a 30-fold increase in the suc-Leu-Leu-Val-Tyr-aminoluciferin substrate (see Fig. S3 in the supplemental material) and complete inhibition of *T. cruzi* proteasome chymotrypsin-like activity by the remaining tested compounds, which are also inhibitors of the trypsin- and caspase-like active sites (Fig. 4; see Table S1), provided favorable evidence for the above-mentioned hypothesis. These findings are in line with those reported by Kirkman et al., who showed that both the  $\beta_2$  and  $\beta_5$  subunits of the *Plasmodium falciparum* proteasome were capable of hydrolysis of the fluorescence-tagged suc-Leu-Leu-Val-Tyr-AMC substrate (26). It is worth noting that bortezomib, ixazomib, and MG132 exhibited biphasic chymotrypsin-like activity dose-response curves. Taking the above into account, it is possible that these biphasic responses were a consequence of suc-Leu-Leu-Val-Tyr-aminoluciferin substrate turnover by the caspase- and/or trypsin-like active sites of the proteasome. For HTS data normalization, a control compound that can abolish *T. cruzi* proteasome catalytic activity would be preferred. With this in mind, and due to its highly potent inhibitory properties, bortezomib was selected as the control inhibitor.

Next, we compared the chymotrypsin-like  $\text{pIC}_{50}$  values (negative logarithm of half-maximal inhibitory concentration [molar]) of the commercial proteasome inhibitors with their  $\text{pEC}_{50}$  values (negative logarithm of half-maximal effective concentration [molar]) obtained using a cellular *T. cruzi* epimastigote viability assay (Fig. 5; see Table S1). All of the tested compounds were found to be active in the cellular assay. Epoxomicin and oprozomib exhibited equipotency between the cell-free chymotrypsin-like activity and cellular assays, while the remaining peptide-based compounds exhibited >10-fold higher potency in the cell-free versus cellular systems. Compared to a cell-free system, protein target engagement by an inhibitor in a cellular






**FIG 4** Cell-free *T. cruzi* proteasome chymotrypsin-like (black circles), trypsin-like (red circles), and caspase-like (green triangles) activity concentration-response curves for a panel of commercially available proteasome inhibitors (i.e., epoxomicin, oprozomib, bortezomib, ixazomib, MG132, and MG115). Data are shown for 4 independent replicates ( $n = 4$ ). The error bars represent SD.


assay is dependent on a number of additional factors, including cellular penetration and retention, which are heavily influenced by the physicochemical properties of the compound, as well as the cellular substrate concentration and affinity. Therefore, it is not unusual for greater inhibitory potency to be observed in a cell-free versus a cellular assay system. The tested compounds can be clustered into peptide epoxyketone, peptide boronate, and peptide aldehyde structural classes (Fig. 6), which target the catalytic active sites of the proteasome. The peptide epoxyketones are known to be irreversible proteasome inhibitors, while the boronate and aldehyde peptide analogues exhibit their effects through reversible binding mechanisms (21, 25, 27). The lower potency in the cellular assay for the last two classes could thus be explained by a presumably high concentration of high-affinity substrates in cells (all proteins that are marked for degradation), which is something that would affect the irreversible inhibitors less.

**High-throughput screening test studies.** Following pharmacological validation of the *T. cruzi* proteasome luminescence-based assay, a number of test screening procedures were undertaken to evaluate the suitability of the assay in a high-throughput format. First, the sensitivity, specificity, and robustness of the platform were tested by



**FIG 5** Correlation of *T. cruzi* proteasome pIC<sub>50</sub> values obtained using cell-free and cellular assays for (from left to right) MG115, oprozomib, epoxomicin, MG132, ixazomib, and bortezomib. Circles, reversible peptide-based inhibitors; triangles, irreversible peptide-based inhibitors. Data are shown for 3 or 4 independent replicates ( $n = 3$  or  $4$ ). The error bars represent SD.

assaying two 384-well microplates that were randomly spiked with the control compound bortezomib at concentrations that were approximately equivalent to the 30% inhibitory concentration (IC<sub>30</sub>), IC<sub>50</sub>, and IC<sub>70</sub> values in this biochemical assay. The assay was found to be highly sensitive, specific, and robust, with a sensitivity of 100%, specificity of 99.4% (see Table S2 in the supplemental material), and Z factor value of 0.87. Next, a “nuisance” set of 1,027 compounds, selected to highlight common biochemical assay interference mechanisms (28), was tested. A good linear correlation was established between screening replicates of this compound set ( $R^2 = 0.95$ ) (see Fig. S4 in the supplemental material). However, a high number of hits that were capable of inhibiting the biochemical response by 30% or more were identified (239 compounds; hit rate = 23.3%). Further evaluation of the interference annotations for these compounds revealed that the assay appeared to be particularly sensitive to interferers with the luciferase enzyme and other mechanisms responsible for a sustained glow-like luminescence response (Table 1).



**FIG 6** Structures of commercially available proteasome inhibitors.



**TABLE 1** Biochemical assay interference mechanisms identified during the screen of the nuisance compound set using the primary *T. cruzi* proteasome chymotrypsin-like activity luminescence-based assay and the secondary luciferase reporter counterscreen assay

Interference mechanism	Total no. <sup>a</sup>	No. of primary-screen hits <sup>b</sup>	Secondary counterscreen	
			No. of hits <sup>b</sup>	% detected <sup>c</sup>
Inhibition of luminescence-coupling system	39	37	33	89
PDELight inhibition	25	20	15	75
Luciferase inhibition	29	17	11	65
DNA binders	65	34	1	3
Redox cyclers	212	30	4	13
Zn chelators	28	5	1	20
Europium donor quenchers	26	2	0	0
Other	1,014	208	23	11


<sup>a</sup>Total number of compounds in the nuisance set annotated with the listed interference mechanism (some compounds contain primary and secondary annotations).

<sup>b</sup>Number of hits identified from nuisance set screens containing primary and/or secondary annotations for the listed interference mechanisms.

<sup>c</sup>Percentage of hits detected by the secondary counterscreen assay relative to the primary screen assay.

### High-throughput counterscreen (technology interference) assay development.

High levels of technology interference during early screening stages of the drug discovery process can translate into large numbers of false-positive hits being selected for follow-up in orthogonal assay hit confirmation studies, which are often resource intensive and have lower throughput. In an attempt to mitigate this issue, our efforts were directed toward developing a secondary high-throughput biochemical counterscreen assay in order to deconvolute luminescence technology interferers from potential *T. cruzi* proteasome inhibitors. By exposing the luciferase reporter component of the proteasome luminescence-based assay system to various concentrations of aminoluciferin substrate, a rapid decline in luminescence signal was observed as substrate was consumed and eventually depleted (Fig. 7a). However, it was noted that when the substrate concentration was sufficiently high (i.e.,  $\geq 2.5 \mu\text{M}$ ), the rapid initial decline in signal was followed by a sustained luminescence response that lasted the duration of




**FIG 7** Luminescence response plotted as a function of time in the presence of various concentrations of aminoluciferin substrate (a) or in the presence (red circles) or absence (black circles) of 4 mM exogenous ATP (b). Data are shown for 4 technical replicates ( $n = 4$ ). The error bars represent SD.

the experiment (i.e., 75 min). Bioluminescence is an ATP-driven process that involves the oxidation of aminoluciferin by a luciferase enzyme, resulting in the generation of a detectable photon. In order to establish a sustained glow-like luminescence response, ATP must be regenerated. Therefore, we envisaged that the luciferase reporter component of the biochemical assay was comprised of an ATP reservoir, which in the presence of sufficient aminoluciferin substrate was rapidly depleted, and the luminescence response became rate limited by ATP regeneration, thereby resulting in a sustained glow-like signal. This was rationalized by the increase in the time taken to reach a sustained luminescence response when the amount of exogenous ATP in the assay system was increased (Fig. 7b). Based on these findings and calculated Z factor values, we selected an aminoluciferin substrate concentration of 5  $\mu$ M (final assay concentration) and a 60-min incubation period as desirable assay conditions.

**High-throughput counterscreen (technology interference) assay validation.** In order to validate the secondary luciferase reporter counterscreen assay, screening of the nuisance compound set was performed using the assay, and a total of 76 hits were identified (hit rate = 7.4%) using a 30% inhibition cutoff threshold. The counterscreen detected a large proportion of interferers with the luciferase enzyme and mechanisms responsible for a sustained glow-like luminescence response that were identified as hits using the primary *T. cruzi* proteasome chymotrypsin-like activity assay (Table 1). The inability of the counterscreen assay to detect all of the luciferase enzyme inhibitor hits could be explained by slight differences in configuration between the counterscreen and primary assays. In the case of the primary screening assay, aminoluciferin was generated *in situ* by the *T. cruzi* proteasome at concentrations presumably lower than those utilized in the counterscreen assay, where an excess of the substrate was required to generate a sustained response. It was therefore likely that the counterscreen assay was less sensitive to competitive inhibitors of the luciferase enzyme than the primary screening assay. It is also important to appreciate that the counterscreen assay was not designed to identify nonspecific sources of technology interference, such as DNA binders and redox cyclers, which were both prominent hits in the primary screening platform, and that some compounds in the nuisance set may be genuine inhibitors of the proteasome. However, it was envisaged that removal of technology interference at the level of the luminescence-based reporter system would sufficiently reduce false-positive hits to allow hit confirmation studies further downstream using lower-throughput orthogonal assay platforms.


**High-throughput screening of diverse compound libraries.** With the appropriate biochemical tools in place, we proceeded by screening two compound libraries comprising a total of 18,098 compounds covering traditional small-molecule chemical space using the primary *T. cruzi* proteasome chymotrypsin-like activity luminescence-based assay at a fixed compound concentration of 9.4  $\mu$ M. Following this effort, we identified 372 compounds (hit rate = 2.1%) capable of inhibiting the biochemical response by 30% or more (Fig. 8). Based on our previous findings, we envisaged that the high hit rate was partially driven by technology interference at the level of the luciferase reporter system. Therefore, as an initial effort to eliminate a proportion of false-positive hits prior to downstream concentration-response assessment, the hit compounds were rescreened using the primary chymotrypsin-like activity assay, as well as the secondary counterscreen assay. By application of fixed  $\geq 30\%$  and  $< 45\%$  inhibition threshold parameters for the former and latter assays, respectively, 180 hits were identified for further evaluation (Fig. 9). Concentration-response assessment of these compounds using the above-mentioned assays was performed, and good linear correlations were obtained between the calculated  $pIC_{50}$  values from the respective assay replicates (see Fig. S5a and b in the supplemental material). Of the 180 hit compounds, 163 were found to be active in the primary *T. cruzi* proteasome chymotrypsin-like activity assay (i.e.,  $pIC_{50} > 4.0$ ) (see Fig. S5a). However, of these, only 39 compounds were found to be completely inactive (i.e.,  $pIC_{50} \leq 4.0$ ) against the secondary counterscreen assay (see Fig. S6 and Table S3 in the supplemental material), with the remaining compounds




**FIG 8** Single-point high-throughput screen of 18,098 structurally diverse compounds at a concentration of 9.4  $\mu\text{M}$  using the primary *T. cruzi* proteasome chymotrypsin-like activity assay. The red circles represent 372 hits exhibiting  $\geq 30\%$  inhibition. Mean Z factor =  $0.91 \pm 0.03$  (SD);  $n = 58$ .

exhibiting some form of technology interference (Fig. 10). Interestingly, the potency correlation between the primary chymotrypsin-like activity and counterscreen assays revealed approximately 5-fold higher  $\text{pIC}_{50}$  values for the former assay than for the counterscreen assay. This skewed relationship could be explained by the presumably lower aminoluciferin substrate concentration present in the primary screening assay than in the counterscreen assay, as described earlier, which would likely make the chymotrypsin-like activity assay more sensitive to potential interferers.

**Conclusions.** We have successfully validated a method for the production and partial purification of *T. cruzi* proteasomes, which we have shown to exhibit the characteristic chymotrypsin-, trypsin-, and caspase-like activities. The isolated protein material was used to adapt a commercially available glow response luminescence-based assay system into a sensitive and specific high-throughput platform aimed at identifying *T. cruzi* proteasome inhibitors. Interestingly, our findings suggested that the suc-Leu-Leu-Val-Tyr-aminoluciferin substrate used in this biochemical assay to probe proteasome chymotrypsin-like activity was not specific for the single type of *T. cruzi* proteasome active site. Instead, it appeared that a fraction of the substrate was being turned over by the trypsin- and/or caspase-like active sites of the protein. Validation of the luminescence-based biochemical assay using a nuisance compound set designed to provide an indication of types of technology interference revealed that the assay was prone to interference at the level of the luciferase reporter. To combat this issue, we developed a high-throughput secondary coun-



**FIG 9** Single-point high-throughput rescreen of 372 initial hit compounds at a concentration of 9.4  $\mu\text{M}$  using the primary *T. cruzi* proteasome chymotrypsin-like activity assay and the secondary technology interference counterscreen assay. The data represent means of two independent replicates per assay ( $n = 2$ ). The red circles represent 180 compounds that exhibited  $\geq 30\%$  and  $< 45\%$  inhibition in the primary and secondary counterscreen assays, respectively. Primary assay mean Z factor =  $0.88 \pm 0.04$  (SD),  $n = 4$ ; counterscreen assay mean Z factor =  $0.79 \pm 0.11$  (SD),  $n = 4$ .



**FIG 10** Plot of the mean  $pIC_{50}$  values ( $n = 2$ ) of 180 hit compounds obtained using the primary *T. cruzi* proteasome chymotrypsin-like activity assay and the secondary counterscreen assay. The red circles represent 39 compounds that were active against the former assay ( $pIC_{50} \geq 4$ ) and inactive against the counterscreen assay ( $pIC_{50} < 4$ ). Primary assay mean Z factor =  $0.67 \pm 0.05$  (SD),  $n = 12$ ; counterscreen assay mean Z factor =  $0.77 \pm 0.04$  (SD),  $n = 12$ .

terscreen assay that was sensitive to both luciferase inhibitors and inhibitors of the ATP regeneration mechanism responsible for a sustained glow-like luminescence response. We then utilized the luminescence-based *T. cruzi* proteasome chymotrypsin-like activity assay to screen a total of 18,098 structurally diverse compounds. Following rescreening and technology interference deconvolution using the secondary counterscreen assay, 39 hits of interest were identified. Further evaluation of these potential *T. cruzi* proteasome inhibitors as new chemical starting points for a Chagas' disease drug discovery program are under way.

## MATERIALS AND METHODS

**General.** The commercially available Proteasome-Glo 3-substrate system and chymotrypsin-like assay kits (Promega; catalogue no. G8531 and G8622, respectively) were assembled according to the manufacturers' protocols (29) unless otherwise stated. Briefly, Proteasome-Glo buffer was used to formulate the luciferin detection reagent (containing a recombinant thermostable luciferase enzyme) to approximately 0.35% (wt/vol) final assay concentration. The luciferin detection reagent was then mixed with Proteasome-Glo trypsin-, caspase-, or chymotrypsin-like reagents (comprising 15  $\mu$ M Z-Leu-Arg-Arg-aminoluciferin (Z is benzyloxycarbonyl), 20  $\mu$ M Z-Nle-Pro-Nle-Asp-aminoluciferin, or 20  $\mu$ M suc-Leu-Leu-Val-Tyr-aminoluciferin substrate, respectively, at final assay concentrations), and the mixture was allowed to incubate at room temperature for 60 min prior to use. *T. cruzi* proteasome buffer comprised 50 mM Tris-HCl, pH 7.5, 10 mM sucrose, 5 mM MgCl<sub>2</sub>, 1 mM dithiothreitol, 2 mM ATP, 150 mM NaCl, 1 mM EDTA, and 0.05 mg/ml bovine serum albumin (BSA). *T. cruzi* strain Silvio X10/7 epimastigotes were maintained *in vitro* at 28°C in RTH-fetal calf serum (FCS) culture medium (RPMI 1640 supplemented with 0.4% Trypticase peptone, 0.017 M HEPES, 25  $\mu$ M hemin, 10% heat-inactivated FCS). Biochemical cell-free assays were performed in an 8- $\mu$ l final assay volume using 384-well white low-volume plates (Greiner; catalogue no. 784904), and cellular assays were performed in a 50- $\mu$ l final assay volume using 384-well standard volume plates (Greiner; catalogue no. 781098). Luminescence was read using an EnVision 2102 Multilabel Reader (PerkinElmer, USA) with 0.2-s per well reading time, unless otherwise specified. DMSO or compound was added to the assay plates using Echo acoustic dispensers (Labcyte, USA). Reagent addition for high-throughput screening assays was performed using an Xrd-384 liquid dispenser (FluidX, United Kingdom) and a BioFill Solo/Xrd-384 8-channel resin nozzle (0.5- to 200- $\mu$ l) tubing cartridge (FluidX; catalogue no. 34-1003). Data analysis was performed using SigmaPlot 12.5 software unless otherwise stated. Z factor values were calculated using the following equation: Z factor =  $1 - \left( \frac{\{3 \times [1.483 \times (\text{RLU MAD Max})] + \{3 \times [1.483 \times (\text{RLU MAD Min})]\}}{\text{median RLU Max} - \text{median RLU Min}} \right)$ , where MAD is the median absolute deviation, Max is the maximum-effect control samples, and Min is the minimum-effect control samples.

***T. cruzi* proteasome production and partial purification.** Mid-log-phase *T. cruzi* strain Silvio X10/7 cells were harvested by centrifugation ( $900 \times g$ ; 35 min). The resulting cell pellet was resuspended in Dulbecco's phosphate-buffered saline (DPBS), and the cells were counted using a Casy Cell counter<sup>+</sup> system;  $2 \times 10^{10}$  cells were pelleted in a 50-ml conical tube ( $900 \times g$ ; 15 min). The cell pellets were then inactivated by three freeze-thaw cycles and stored at  $-80^{\circ}\text{C}$ . To validate biological inactivation, approximately 10% of the pellet by weight was resuspended in RTH-FCS medium and incubated at 28°C for 6 weeks. Absence of cell growth after 6 weeks was considered evidence of inactivation. For proteasome purification, *T. cruzi* pellets were thawed on ice, resuspended, and diluted in an equal volume of double-strength sucrose lysis buffer (100 mM Tris-HCl, pH 7.5, 500 mM sucrose, 10 mM

MgCl<sub>2</sub>, 2 mM dithiothreitol, 4 mM ATP, 100 mM NaCl, 2 mM EDTA), followed by further dilution using single-strength sucrose lysis buffer to afford a cellular concentration of  $2 \times 10^9$  cells/ml. The resulting suspension was passed through a continuous-flow cell disruptor (Constant Systems Limited, United Kingdom) at 20,000 lb/in<sup>2</sup> to lyse the cells. The lysate was then clarified by centrifugation at  $20,000 \times g$  at 4°C for 30 min, and the resulting supernatant was ultracentrifuged at  $300,000 \times g$  at 4°C for 120 min to form a pellet. The pellet was then resuspended using 2 ml of *T. cruzi* proteasome buffer (without BSA) per liter of original *T. cruzi* growth and solubilized by rolling at 4°C for 30 to 60 min. Insoluble material was removed by centrifugation at  $20,000 \times g$  at 4°C for 20 min. The sample was then passed through a 0.2- $\mu$ m syringe filter and purified using a 100-ml Superose 6 gel filtration column (GE Healthcare) at a flow rate of 0.5 ml/min.

**Activity-based characterization of *T. cruzi* proteasome.** Four microliters of each undiluted 2-ml gel filtration fraction was incubated at room temperature with either epoxomicin (Sigma-Aldrich; catalogue no. E3652; 5  $\mu$ M and 0.5% [vol/vol] DMSO final concentrations) or DMSO (0.5% [vol/vol] final assay concentration) at room temperature for 60 min. Next, 4  $\mu$ l of the luciferin detection and Proteasome-Glo chymotrypsin-like reagent mixture was added to initiate the biochemical reaction. The reaction was allowed to proceed at room temperature for 20 min, after which the luminescence was read. Data were acquired from a single replicate ( $n = 1$ ). Gel filtration fractions displaying chymotrypsin-like activity amenable to epoxomicin inhibition were pooled (see Fig. S1 in the supplemental material). Four microliters of the pooled protein material was then added to 4  $\mu$ l of luciferin detection and Proteasome-Glo chymotrypsin-, trypsin-, or caspase-like reagent mixtures in the presence of either epoxomicin (5  $\mu$ M and 0.5% [vol/vol] DMSO final assay concentrations) or DMSO (0.5% [vol/vol] final assay concentration). Luminescence was read immediately and then every 90 s for 75 min. Data were acquired from 6 technical replicates ( $n = 6$ ).

**Primary assay development and kinetic-parameter determination.** Assay linearity and the optimal amount of *T. cruzi* proteasome for screening was determined by first serially diluting (1 in 2; CMF = 0.5) the proteasome stock solution in proteasome buffer to generate 10 additional concentrations. Next, 4  $\mu$ l of each of the *T. cruzi* proteasome solutions was added to 4  $\mu$ l of the luciferin detection and Proteasome-Glo chymotrypsin-like reagent mixture. Luminescence was read immediately and then every 90 s for 75 min. Data were acquired from 5 technical replicates ( $n = 5$ ). To calculate the Michaelis constant ( $K_m$ ) and identify the optimal amount of chymotrypsin-like suc-Leu-Leu-Val-Tyr-aminoluciferin substrate for screening, the Proteasome-Glo chymotrypsin-like assay (Promega; catalogue no. G8622) luciferin detection reagent (comprising luciferase enzyme in Proteasome-Glo buffer) was prepared according to the manufacturers' protocol (29). A 1,200  $\mu$ M solution (600  $\mu$ M final assay concentration) of the substrate was prepared and subsequently serially diluted (1 in 2; CMF = 0.5) using the luciferin detection reagent to generate 8 additional concentrations. Next, 4  $\mu$ l of each of the luciferin detection and substrate solution mixtures was added to 4  $\mu$ l of partially purified *T. cruzi* proteasome that was diluted 1 in 4 (CMF = 0.25) from the original stock using proteasome buffer. Luminescence was read immediately and then every 90 s for 75 min. Data were acquired from 3 technical replicates ( $n = 3$ ). The  $K_m$  was obtained by fitting all of the individual replicate data to the Michaelis-Menten equation shown below ([S] is substrate concentration):

$$v = \frac{V_{\max}[S]}{K_m + [S]}$$

**DMSO tolerance.** Partially purified *T. cruzi* proteasome stock solution was diluted 1 in 4 (CMF = 0.25) using proteasome buffer, and 4  $\mu$ l of the diluted solution was added to various volumes of DMSO (corresponding to 1% [vol/vol], 0.5% [vol/vol], 0.25% [vol/vol], and 0.125% [vol/vol] final assay concentrations). Next, 4  $\mu$ l of the luciferin detection and Proteasome-Glo chymotrypsin-like reagent mixture was added to initiate the biochemical reaction. Luminescence was read immediately and then every 90 s for 75 min. Data were acquired from 6 technical replicates ( $n = 6$ ).

**Cell-free pIC<sub>50</sub> determinations for commercial compounds.** Partially purified *T. cruzi* proteasome stock solution was diluted 1 in 4 (CMF = 0.25) using proteasome buffer, and 4  $\mu$ l of the diluted solution was incubated at room temperature for 60 min in various concentrations of compound (oprozomib, bortezomib, ixazomib, and MG132 [Selleckchem; catalogue no. S7049, S1013, S2180, and S2619 respectively]; MG115 [Enzo Life Sciences; catalogue no. ALX-260-091-M005]; epoxomicin [Sigma-Aldrich; catalogue no. E3652]) (12 final assay concentrations ranging from  $3.09 \times 10^{-5}$  M to  $1.11 \times 10^{-9}$  M at 1-in-3 dilution increments). Next, 4  $\mu$ l of luciferin detection and Proteasome-Glo chymotrypsin-, caspase-, or trypsin-like reagent mixtures were added to initiate the biochemical reaction. The reaction was allowed to proceed at room temperature for 60 min, after which the luminescence was read. Data were acquired from 4 independent replicates ( $n = 4$ ). Relative luminescence unit (RLU) data were normalized to percent inhibition values relative to 100% effect (DMSO, 1% [vol/vol] final assay concentration in the absence of *T. cruzi* proteasome enzyme) and 0% effect (DMSO, 1% [vol/vol] final assay concentration with *T. cruzi* proteasome enzyme) control populations using Microsoft Excel 2013 software. IC<sub>50</sub> values were calculated by fitting the concentration-response data for each independent replicate separately to either a four-parameter logistic model or a seven-parameter logistic model with the bottom curve plateau parameter constrained to zero, as shown below.

The four-parameter logistic model is as follows:

$$y = \text{Min} + \frac{\text{Max} - \text{Min}}{1 + \left(\frac{x}{\text{IC}_{50}}\right)^{-\text{Hillslope}}}$$



The seven-parameter logistic model is as follows:

$$y = \left( \text{Max}_1 + \left\{ \frac{\text{Min} - \text{Max}_1}{1 + \left[ \left( \frac{x}{\text{IC}_{50-1}} \right)^{\text{Hillslope}_1} \right]} \right\} \right) + \left( \text{Max}_2 - \left\{ \frac{\text{Max}_2}{1 + \left[ \left( \frac{x}{\text{IC}_{50-2}} \right)^{\text{Hillslope}_2} \right]} \right\} \right)$$

The  $\text{IC}_{50}$  parameters were then used to calculate the  $\text{pIC}_{50}$  values using the following equation, followed by a calculation of a mean  $\text{pIC}_{50}$  for each compound:  $\text{pIC}_{50} = \{-\log(\text{IC}_{50}[\text{M}])\}$ . Where biphasic concentration-response curves were observed,  $\text{pIC}_{50}$  values for the dominant curve were reported. Figures were generated by fitting the mean concentration-response data for each compound using the above-mentioned models.

**Cell-free concentration-response relationships using 20  $\mu\text{M}$  and 600  $\mu\text{M}$  substrate.** The Proteasome-Glo chymotrypsin-like assay (Promega; catalogue no. G8622) luciferin detection reagent (comprising luciferase enzyme in Proteasome-Glo buffer) was prepared according to the manufacturer's protocol (29). A 1,200  $\mu\text{M}$  (600  $\mu\text{M}$  final assay concentration) and a 40  $\mu\text{M}$  (20  $\mu\text{M}$  final assay concentration) solution of Proteasome-Glo chymotrypsin-like reagent were prepared using the luciferin detection reagent as a diluent, and the mixtures were incubated at room temperature for 60 min. Partially purified stock *T. cruzi* proteasome solution was diluted 1 in 4 ( $\text{CMF} = 0.25$ ) using proteasome buffer, and 4  $\mu\text{l}$  of the diluted solution was added to various concentrations of oprozomib (Selleckchem; catalogue no. S7049) (12 final assay concentrations ranging from  $3.09 \times 10^{-5}$  M to  $1.11 \times 10^{-9}$  M at 1-in-3 dilution increments). Next, 4  $\mu\text{l}$  of either 40  $\mu\text{M}$  or 1,200  $\mu\text{M}$  Proteasome-Glo chymotrypsin-like reagent was added to initiate the biochemical reaction. The reaction was allowed to proceed at room temperature for 60 min, after which the luminescence was read. Data were acquired from 3 independent replicates ( $n = 3$ ) and processed as described above for the cell-free  $\text{pIC}_{50}$  determination experiments.

**Cellular  $\text{pEC}_{50}$  determinations for commercial compounds.** *T. cruzi* strain Silvio X10/7 epimastigotes (25  $\mu\text{l}$  at  $5 \times 10^5$  cells/ml) were incubated at 28°C in 5%  $\text{CO}_2$  for 96 h in either a fixed concentration of control compound (Nifurtimox; Sigma-Aldrich; catalogue no. N3415-25MG;  $4.98 \times 10^{-5}$  M final assay concentration) or various concentrations of test compound (oprozomib, bortezomib, ixazomib, MG132, MG115, and epoxomicin; 10 final assay concentrations ranging from  $4.98 \times 10^{-5}$  M to  $2.49 \times 10^{-9}$  M at 1-in-3 dilution increments). For the cell viability readout, BacTiter-Glo microbial cell viability reagent (Promega; catalogue no. G8230) was added to each well (25  $\mu\text{l}$ ) and incubated at room temperature for 5 min. The plates were then sealed with clear film, and the luminescence was read using a Victor 3 (PerkinElmer, USA) or Pherastar F5 (BMG Labtech, Germany) plate reader with a 0.5-s per well reading time. Data for epoxomicin were obtained from three independent replicates ( $n = 3$ ), and data for all the remaining compounds were acquired from four independent replicates ( $n = 4$ ). RLU data were normalized to percent inhibition values relative to 100% effect (Nifurtimox) and 0% effect (DMSO; 1% [vol/vol] final assay concentration) control populations. Normalized data for each independent replicate were fitted separately to a four-parameter logistic regression model, and  $\text{pEC}_{50}$  [i.e.,  $-\log(\text{EC}_{50}[\text{M}])$ ] values were calculated using IBDS ActivityBase 8.1.2.12 software, after which a mean  $\text{pEC}_{50}$  value for each compound was calculated.

**Secondary counterscreen assay development.** In order to identify the optimum amount of amino-luciferin substrate (Stratech; catalogue no. 13415-AAT) for screening, a 20  $\mu\text{M}$  solution (10  $\mu\text{M}$  final assay concentration) of substrate was prepared and subsequently serially diluted (1 in 2;  $\text{CMF} = 0.5$ ) using the proteasome buffer to generate 10 additional concentrations. To test the dependence of the assay on exogenous ATP, 10  $\mu\text{M}$  aminoluciferin substrate solutions (5  $\mu\text{M}$  final assay concentration) were also prepared in proteasome buffer either lacking ATP (buffer A) or containing 4 mM ATP (buffer B). Next, 4  $\mu\text{l}$  of each of the substrate solutions was added to 4  $\mu\text{l}$  of luciferin detection reagent. Luminescence was read immediately and then every 90 s for 75 min. Data were acquired from 5 technical replicates for each experiment ( $n = 5$ ).

**High-throughput screening test studies.** To test assay sensitivity, specificity, and suitability in a high-throughput format, partially purified stock *T. cruzi* proteasome solution was diluted 1 in 8 ( $\text{CMF} = 0.125$ ) using proteasome buffer, and 4  $\mu\text{l}$  of the diluted solution was added to two assay plates containing bortezomib (Selleckchem; catalogue no. S1013). The bortezomib was randomly distributed across a total of 22 positions per plate at final assay concentrations approximately equivalent to the  $\text{IC}_{70}$  (79 nM; DMSO, 1% [vol/vol]),  $\text{IC}_{50}$  (17 nM; DMSO, 1% [vol/vol]), and  $\text{IC}_{30}$  (4 nM; DMSO, 1% [vol/vol]) values for the compound. With the exception of the control columns, all the remaining plate wells contained DMSO only (1% [vol/vol] final assay concentration). The plates were allowed to incubate at room temperature for 60 min, after which 4  $\mu\text{l}$  of Proteasome-Glo chymotrypsin-like reagent was added to initiate the biochemical reaction. The reaction was allowed to proceed at room temperature for 60 min, after which the luminescence was read. RLU values were normalized to percent inhibition values relative to 100% effect (10  $\mu\text{M}$  bortezomib and DMSO, 1% [vol/vol] final assay concentrations) and 0% effect (DMSO, 1% [vol/vol] final assay concentration) control populations using Microsoft Excel 2013 software. A hit identification threshold of 30% inhibition was set, and the percent sensitivity and percent specificity were calculated using the following equations: percent sensitivity =  $[\text{TP}/(\text{TP} + \text{FN})] \times 100$ , where TP is true positive and FN is false negative, and percent specificity =  $[\text{TN}/(\text{FP} + \text{TN})] \times 100$ , where TN is true negative and FP is false positive.

**Single-point high-throughput screening.** In the case of the primary assay, 4  $\mu\text{l}$  of partially purified *T. cruzi* proteasome that was diluted 1 in 8 ( $\text{CMF} = 0.125$ ) from the original stock using proteasome buffer was added to assay plates containing either technology interference nuisance compounds (1,027 compounds; 10  $\mu\text{M}$  and, for DMSO, 1% [vol/vol] final assay concentrations) or structurally diverse compounds exploring drug-like chemical space from the Dundee Drug Discovery Unit library (9,257 compounds) and Global Health Chemical Diversity Library (GHCDL) (8,841



compounds) (9.4  $\mu$ M and, for DMSO, 1% [vol/vol] final assay concentrations). The plates were allowed to incubate at room temperature for 60 min, after which 4  $\mu$ l of luciferin detection and Proteasome-Glo chymotrypsin-like reagent mixture was added to initiate the biochemical reaction. The reaction was allowed to proceed at room temperature for 60 min, after which the luminescence was read. For the secondary counterscreen assay, 4  $\mu$ l of 10  $\mu$ M aminoluciferin solution (5  $\mu$ M final assay concentration) formulated in proteasome buffer was added to the compound-containing assay plates, followed by 4  $\mu$ l of luciferin detection reagent to initiate the biochemical reaction. The plates were allowed to incubate at room temperature for 60 min, after which the luminescence was read. RLU values were normalized to percent inhibition values relative to 100% effect (9.4  $\mu$ M bortezomib and 1% [vol/vol] DMSO final assay concentrations for the primary assay and 1% [vol/vol] DMSO in the absence of luciferase detection reagent for the secondary counterscreening assay) and 0% effect (DMSO, 1% [vol/vol] final assay concentration) control populations. For the nuisance compound set, primary assay screening data were acquired from 2 independent replicates ( $n = 2$ ), while the secondary assay counterscreen data were acquired from a single replicate ( $n = 1$ ). For initial single-point high-throughput screening of the two diversity compound sets, data were acquired from a single replicate ( $n = 1$ ) and follow-up screening data on identified hits using both the primary and secondary counterscreen assays were acquired for two independent replicates ( $n = 2$ ). Compounds exhibiting  $\geq 30\%$  and  $\geq 45\%$  inhibition in the primary and secondary counterscreen assays, respectively, were identified as hits. Data were processed using IBDS ActivityBase 8.1.2.12 and Dotmatics Limited Vortex v2017.08.69598-59-s software.

**Hit compound cell-free pIC<sub>50</sub> determinations.** Primary screen and secondary counterscreen biochemical assays were performed as described above for the single-point high-throughput screening experiments using assay plates containing various concentrations of compound (10 final assay concentrations ranging from  $9.90 \times 10^{-5}$  M to  $5.52 \times 10^{-9}$  M at 1-in-3 dilution increments). Data were acquired from 2 independent replicates ( $n = 2$ ) for both the primary and counterscreen assays and were subsequently processed using IBDS ActivityBase 8.1.2.12 and Dotmatics Limited Vortex v2017.08.69598-59-s software. pIC<sub>50</sub> values were determined by fitting the data to a four-parameter logistic model.

**Ancillary information.** The supplemental material includes fraction testing of the *T. cruzi* proteasome, chymotrypsin-like activity in the presence of different concentrations of DMSO, cell-free pIC<sub>50</sub> and cellular pEC<sub>50</sub> values for commercial inhibitors, concentration-response curves for oprozomib in the presence of low and high substrate, primary biochemical assay sensitivity and specificity calculations, a high-throughput screen of nuisance set compounds, pIC<sub>50</sub> correlation plots for primary and secondary counterscreen assay replicates, structures of 39 hit compounds, and primary assay pIC<sub>50</sub> values for the 39 hit compounds.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.00309-19>.

**SUPPLEMENTAL FILE 1**, PDF file, 0.5 MB.

## ACKNOWLEDGMENTS

We acknowledge the Wellcome Trust for funding (grants 204672/Z/16/Z and 203134/Z/16/Z) and the support of the Drug Discovery Unit compound management and data management teams. We also acknowledge GlaxoSmithKline (GSK) for provision of the nuisance compound set for screening against the *T. cruzi* proteasome primary and counterscreen assays.

We have no conflicting interests.

F.Z., L.S.T., and M.D.R. conceived the research; F.Z. and M.D.R. wrote the manuscript with scientific input from L.S.T., D.W.G., S.M.S., and L.S.; F.Z. developed the primary and counterscreen biochemical assays, performed the validation and screening experiments, and analyzed the data; D.J. developed the methods for *T. cruzi* parasite growth and inactivation and, together with L.S., produced the lysates for *T. cruzi* proteasome purification; S.M.S. developed the methods for partial purification of the *T. cruzi* proteasome and, together with A.S., supplied the partially purified protein for assay development and screening; L.S. performed the cellular potency assays; P.D.C. preprocessed the raw screening data from the nuisance sets; and A.C. provided the interference annotations for the nuisance compound set hits.

## REFERENCES

1. Conners EE, Vinetz JM, Weeks JR, Brouwer KC. 2016. A global systematic review of Chagas disease prevalence among migrants. *Acta Trop* 156: 68–78. <https://doi.org/10.1016/j.actatropica.2016.01.002>.
2. Perez-Molina JA, Molina I. 2018. Chagas disease. *Lancet* 391:82–94. [https://doi.org/10.1016/S0140-6736\(17\)31612-4](https://doi.org/10.1016/S0140-6736(17)31612-4).
3. Sabino EC, Ribeiro AL, Salemi VM, Di Lorenzo Oliveira C, Antunes AP,

- Menezes MM, Ianni BM, Nastari L, Fernandes F, Patavino GM, Sachdev V, Capuani L, de Almeida-Neto C, Carrick DM, Wright D, Kavounis K, Gonzalez TT, Carneiro-Proietti AB, Custer B, Busch MP, Murphy EL. 2013. Ten-year incidence of Chagas cardiomyopathy among asymptomatic *Trypanosoma cruzi*-seropositive former blood donors. *Circulation* 127: 1105–1115. <https://doi.org/10.1161/CIRCULATIONAHA.112.123612>.
4. Sperandio da Silva GM, Felix Mediano MF, Hasslocher-Moreno AM, Holanda MT, Silvestre de Sousa A, Sangesis LHC, Brasil PEAAD, Mejia RA, Fux CP, Cubides J-C, Saraiva RM, Brum-Soares LM. 2017. Benzimidazole treatment safety: the Medecins Sans Frontieres experience in a large cohort of Bolivian patients with Chagas' disease. *J Antimicrob Chemother* 72:2596–2601. <https://doi.org/10.1093/jac/dkx180>.
  5. Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo M-J, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I, Santana G, Blum B, Correia E, Garcia-Bournisen F, Vaillant M, Morales JR, Pinto Rocha JJ, Rojas Delgadillo G, Magne Anzoleaga HR, Mendoza N, Quechover JC, Caballero MYE, Lozano Beltran DF, Zalabar AM, Rojas Panozo L, Palacios Lopez A, Torrico Terceros D, Fernandez Galvez VA, Cardozo L, Cuellar G, Vasco Arenas RN, Gonzales I, Hoyos Delfin CF, Garcia L, Parrado R, de la Barra A, Montano N, Villarroel S, Duffy T, Bisio M, Ramirez JC, Duncanson F, Everson M, Daniels A, Asada M, Cox E, Wesche D, Diderichsen PM, Marques AF, Izquierdo L, Sender SS, Reverter JC, Morales M, Jimenez W. 2018. Treatment of adult chronic indeterminate Chagas disease with benzimidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. *Lancet Infect Dis* 18:419–430. [https://doi.org/10.1016/S1473-3099\(17\)30538-8](https://doi.org/10.1016/S1473-3099(17)30538-8).
  6. Molina I, Gómez I, Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valero L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A. 2014. Randomized trial of posaconazole and benzimidazole for chronic Chagas' disease. *N Engl J Med* 370:1899–1908. <https://doi.org/10.1056/NEJMoa1313122>.
  7. Peña I, Manzano MP, Cantizani J, Kessler A, Alonso-Padilla J, Bardera AI, Alvarez E, Colmenarejo G, Cotoillo I, Roquero I, de Dios-Anton F, Barroso V, Rodriguez A, Gray DW, Navarro M, Kumar V, Sherstnev A, Drewry DH, Brown JR, Fiandor JM, Martin JJ. 2015. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. *Sci Rep* 5:8771. <https://doi.org/10.1038/srep08771>.
  8. National Center for Biotechnology Information. 2010. Probe reports from the NIH Molecular Libraries Program. <https://www.ncbi.nlm.nih.gov/books/NBK47352/>.
  9. Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, Barnes SW, Mathison CJN, Myburgh E, Gao M-Y, Gillespie JR, Liu X, Tan JL, Stinson M, Rivera IC, Ballard J, Yeh V, Groessl T, Federe G, Koh HXY, Venable JD, Bursulaya B, Shapiro M, Mishra PK, Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SPS, Wen BG, Walker JR, Tuntland T, Molteni V, Glynne RJ, Supek F. 2016. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. *Nature* 537:229–233. <https://doi.org/10.1038/nature19339>.
  10. Keenan M, Alexander PW, Chaplin JH, Abbott MJ, Diao H, Wang Z, Best WM, Perez CJ, Cornwall SM, Keatley SK, Thompson RC, Charman SA, White KL, Ryan E, Chen G, Ioset JR, von Geldern TW, Chatelain E. 2013. Selection and optimization of hits from a high-throughput phenotypic screen against *Trypanosoma cruzi*. *Future Med Chem* 5:1733–1752. <https://doi.org/10.4155/fmc.13.139>.
  11. Alonso-Padilla J, Rodríguez A. 2014. High throughput screening for anti-*Trypanosoma cruzi* drug discovery. *PLoS Negl Trop Dis* 8:e3259. <https://doi.org/10.1371/journal.pntd.0003259>.
  12. Chatelain E, Ioset JR. 2018. Phenotypic screening approaches for Chagas disease drug discovery. *Expert Opin Drug Discov* 13:141–153. <https://doi.org/10.1080/17460441.2018.1417380>.
  13. Wyllie S, Brand S, Thomas M, De Rycker M, Chung C, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrían D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko E, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Gaza EV, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG. 2019. Preclinical candidate for the treatment of visceral leishmaniasis that act through proteasome inhibition. *Proc Natl Acad Sci U S A* 116:9318–9323. <https://doi.org/10.1073/pnas.1820175116>.
  14. Ciechanover A. 2017. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. *Best Pract Res Clin Haematol* 30: 341–355. <https://doi.org/10.1016/j.beha.2017.09.001>.
  15. Cromm PM, Crews CM. 2017. The proteasome in modern drug discovery: second life of a highly valuable drug target. *ACS Cent Sci* 3:830–838. <https://doi.org/10.1021/acscentsci.7b00252>.
  16. Kisselev AF, Goldberg AL. 2015. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. *Methods Enzymol* 398:364–378. [https://doi.org/10.1016/S0076-6879\(05\)98030-0](https://doi.org/10.1016/S0076-6879(05)98030-0).
  17. Tanaka K. 2009. The proteasome: overview of structure and functions. *Proc Jpn Acad Ser B* 85:12–36. <https://doi.org/10.2183/pjab.85.12>.
  18. Ng CL, Fidock DA, Bogoy M. 2017. Protein degradation systems as antimalarial therapeutic targets. *Trends Parasitol* 33:731–743. <https://doi.org/10.1016/j.pt.2017.05.009>.
  19. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O, Weir A. 2015. An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nat Rev Drug Discov* 14:475–486. <https://doi.org/10.1038/nrd4609>.
  20. O'Brien MA, Moravec RA, Riss TL, Bulleit RF. 2015. Homogenous, bioluminescent proteasome assays. *Methods Mol Biol* 1219:95–114. [https://doi.org/10.1007/978-1-4939-1661-0\\_9](https://doi.org/10.1007/978-1-4939-1661-0_9).
  21. Kisselev AF, Goldberg AL. 2001. Proteasome inhibitors: from research tools to drug candidates. *Chem Biol* 8:739–758. [https://doi.org/10.1016/S1074-5521\(01\)00056-4](https://doi.org/10.1016/S1074-5521(01)00056-4).
  22. Meng L, Mohan R, Kwok BHB, Elofsson M, Sin N, Crews CM. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. *Proc Natl Acad Sci U S A* 96:10403–10408. <https://doi.org/10.1073/pnas.96.18.10403>.
  23. Stein RL, Melandri F, Dick L. 1996. Kinetic characterization of the chymotryptic activity of the 20S proteasome. *Biochemistry* 35:3899–3908. <https://doi.org/10.1021/bi952262x>.
  24. Zhang J, Chung TDY, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. *J Biomol Screen* 4:67–73. <https://doi.org/10.1177/108705719900400206>.
  25. Zhou H-J, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlafi F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J. 2009. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). *J Med Chem* 52: 3028–3038. <https://doi.org/10.1021/jm801329v>.
  26. Kirkman LA, Zhan W, Visone J, Dziedzic A, Singh PK, Fan H, Tong X, Bruzual I, Hara R, Kawasaki M, Imaeda T, Okamoto R, Sato K, Michino M, Alvaro EF, Guiang LF, Sanz L, Mota DJ, Govindasamy K, Wang R, Ling Y, Tumwebaze PK, Sukenick G, Shi L, Vendome J, Bhanot P, Rosenthal PJ, Aso K, Foley MA, Cooper RA, Kafsack B, Doggett JS, Nathan CF, Lin G. 2018. Antimalarial proteasome inhibitor reveals collateral sensitivity from inter-subunit interactions and fitness cost of resistance. *Proc Natl Acad Sci U S A* 115:E6863–E6870. <https://doi.org/10.1073/pnas.1806109115>.
  27. Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, Yu J, Yang Y, Hales P, Bruzzese F, Liu J, Blank J, Garcia K, Tsu C, Dick L, Fleming P, Yu L, Manfredi M, Rolfe M, Bolen J. 2010. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. *Cancer Res* 70:1970–1980. <https://doi.org/10.1158/0008-5472.CAN-09-2766>.
  28. Chakravory SJ, Chan J, Greenwood MN, Papa-Burke I, Remlinger KS, Pickett SD, Green DVS, Fillmore MC, Dean TW, Luengo JI, Macarrón R. 2018. Nuisance compounds, PAINS filters, and dark chemical matter in the GSK HTS collection. *SALS Discov* 23:532–545. <https://doi.org/10.1177/2472555218768497>.
  29. Promega. 2016. Technical bulletin. Proteasome-Glo assay systems. Instructions for use of products G8531, G8532, G8621, G8622, G8632, G8641 and G8642. [https://www.promega.co.uk/products/small-molecule-drug-discovery/drug-discovery-workflow/primary-screening/proteasome\\_glo-assays/?catNum=G8532](https://www.promega.co.uk/products/small-molecule-drug-discovery/drug-discovery-workflow/primary-screening/proteasome_glo-assays/?catNum=G8532).